Form 4: Annexon EVP Granted Equity Awards

Annexon, Inc.'s EVP & Chief Scientific Officer, Dean Richard Artis, was granted 62,500 restricted stock units and 250,000 stock options.

Summary

• Dean Richard Artis, Executive Vice President and Chief Scientific Officer of Annexon, Inc., was granted equity awards.
• The awards consist of 62,500 Restricted Stock Units (RSUs) and 250,000 stock options.
• Each RSU entitles the reporting person to receive one share of Common Stock upon vesting.
• The RSUs will vest in three equal annual installments, with the first third vesting on February 19, 2027.
• The stock options have an exercise price of $5.1 per share and are set to expire on February 19, 2036.
• The stock options will vest monthly over a four-year period, with full vesting achieved on February 19, 2030.
• All vesting for both RSUs and stock options is contingent upon Mr. Artis's continuous service with Annexon, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating the company's commitment to retaining and incentivizing a key executive, which can contribute to long-term stability and strategic execution.

Positives

• The granting of equity awards aligns the executive's financial interests with those of the shareholders, promoting long-term value creation.
• These awards serve as an incentive for the executive's continued commitment and performance, which is crucial for a key scientific leadership role.

Negatives

• The future conversion of RSUs into shares and the exercise of stock options could lead to a degree of dilution for existing shareholders.

Future Outlook

The filing does not provide a future outlook for the company's operations or financial performance, focusing solely on an insider's equity transactions.

Industry Context

StockSavvy.ai notes that equity grants to key executives like a Chief Scientific Officer are a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize top talent, aligning their long-term interests with the company's success in drug development and commercialization.

Comparison to Industry Standards

• StockSavvy.ai observes that the structure of these equity grants, including a mix of RSUs and stock options with multi-year vesting schedules, is consistent with compensation practices for senior executives in comparable biotech firms.
• Similar long-term incentive plans are common at companies like BioNTech or Moderna, where executive compensation is heavily weighted towards equity to reward successful R&D milestones and market performance.

Related Party Transactions

• Grant of 62,500 Restricted Stock Units to Dean Richard Artis, an Executive Vice President and Chief Scientific Officer.
• Grant of 250,000 Stock Options to Dean Richard Artis, an Executive Vice President and Chief Scientific Officer.

Stakeholder Impact

• Shareholders: Potential for future dilution upon the vesting and exercise of these equity awards.
• Employees: May signal confidence in the company's future and serve as an example of executive compensation structure.
• Executive (Dean Richard Artis): Receives significant long-term incentive compensation tied to company performance and continued service.

Next Steps

• Vesting of 1/3rd of the granted RSUs on February 19, 2027.
• Monthly vesting of stock options commencing February 19, 2026, leading to full vesting by February 19, 2030.

Key Dates

Keywords

Annexon, ANNX, insider transaction, Form 4, restricted stock units, RSUs, stock options, equity grant, executive compensation, Dean Richard Artis